Safety and activity of autologous T cells with enhanced NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-a*02(+) previously-treated and - untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO) Meeting Abstract

  

Authors:	D'Angelo, S. P.; Blay, J. Y.; Chow, W. A.; Demetri, G. D.; Thistlethwaite, F.; Sen, S.; Razak, A. R. A.; Haanen, J. B. A. G.; Noujaim, J. C.; Johnson, M. L.; Laetsch, T. W.; Chiou, V. L.; Pearce, L.; Faitg, T. H.; Ji, R.; Johnson, L. A.; Shalabi, A. M.; Thornton, K. A.; Mackall, C.; Van Tine, B. A.
Abstract Title:	Safety and activity of autologous T cells with enhanced NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-a*02(+) previously-treated and - untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO)
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Language:	English
ACCESSION:	WOS:000560368309037
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.TPS11571
Notes:	Meeting Abstract: TPS11571 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/179108